Notably, G6PD, which is the rate limiting enzyme of the oxidative phase of PPP, has been shown to be aberrantly activated in HR+ breast cancer and contributes to tumor development and progression through decreased cellular autophagy, tumor relapse and drug resistance in breast cancer models. The gene discussed is G6PD; the disease is neoplasm.